Registro completo de metadatos
| Campo DC | Valor | Lengua/Idioma |
|---|---|---|
| dc.creator | Robles-Garcia, J.E. (José Enrique) | - |
| dc.creator | Zudaire-Bergera, J.J. (Juan Javier) | - |
| dc.creator | Rosell, D. (David) | - |
| dc.creator | Berian-Polo, J.M. (José María) | - |
| dc.date.accessioned | 2014-03-10T12:15:08Z | - |
| dc.date.available | 2014-03-10T12:15:08Z | - |
| dc.date.issued | 2005 | - |
| dc.identifier.citation | Robles García JE, Zudaire Bergera JJ, Rosell Costa D, Berián Polo JM. Nuevos fármacos en el tratamiento de la incontinencia urinaria . Rev Med Univ Navarra. 2004 Oct-Dec;48(4):43-9. | es_ES |
| dc.identifier.issn | 0556-6177 | - |
| dc.identifier.uri | https://hdl.handle.net/10171/35415 | - |
| dc.description.abstract | Several classes of drugs have been investigated for their efficacy in treating overactive bladder syndrome (OAB) and stress urinary incontinence (SUI). Surgery and behavioral therapies are currently the mainstay of treating SUI. However, results are also being made available about a new oral medication, Duloxetine, which appears to be clinically safe and effective for the treatment of SUI. On the other hand, a new muscarinic receptor antagonist, Solifenacin, has been shown in clinical trials to be clinically effective, safe and well tolerated for treating OAB | es_ES |
| dc.language.iso | spa | es_ES |
| dc.publisher | Ediciones Universidad de Navarra | es_ES |
| dc.rights | info:eu-repo/semantics/openAccess | es_ES |
| dc.rights | info:eu-repo/semantics/openAccess | es_ES |
| dc.subject | Incontinencia urinaria de esfuerzo | es_ES |
| dc.subject | Duloxetina | es_ES |
| dc.subject | Vejiga hiperactiva | es_ES |
| dc.subject | Solifenacina | es_ES |
| dc.title | Nuevos fármacos en el tratamiento de la incontinencia urinaria | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.
